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resistance in S. aureus. Travel to South Asia was associated with
the highest risk of acquiring trimethoprim–sulfamethoxazole-Clinical Microbiology and Infection © 2015 European Society of Cresistant S. aureus. We conclude that globally dfrG is the
predominant determinant of trimethoprim resistance in human
S. aureus infection.
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chemotherapies increasingly forces infectious diseases practi-
tioners to resort to rediscovering ‘old antibiotics’ [1]. Trimeth-
oprim–sulfamethoxazole has seen a renaissance for the
treatment of skin and soft-tissue infections (SSTI) caused by
methicillin-resistant S. aureus (MRSA) in Europe [2] and North
America [3], where most isolates are susceptible. The recent
observation that trimethoprim–sulfamethoxazole, in combina-
tion with rifampicin is non-inferior to linezolid for the treatment
of severe staphylococcal infections [4] illustrates the renewed
interest in, and potential of, antifolate compounds. However,
research on imported S. aureus and from Africa strongly suggests
that trimethoprim–sulfamethoxazole resistance is emerging
around the globe [5–8], reaching up to 44% in South Asia [8].
Here, we analyse a geographically and genetically diverse
collection of imported S. aureus from returnees treated for
SSTI. We aim to describe the contribution of trimethoprim
resistance and its genetic determinants towards the global up-
surge in trimethoprim–sulfamethoxazole resistance in S. aureus
causing human infections.
From May 2011 to December 2013, swab materials and
patient information from travel-associated SSTI were collected
at 13 travel clinics across Europe (www.staphtrav.eu) [8].
For comparison, we used consecutive S. aureus isolates from
outpatients with acute onset SSTI treated at the Department ofClin Microbiol Infect 2015; 21: 1095.e5–1095.e9
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2014. Materials taken from patients with chronic wounds,
hospitalization or travel outside Europe 3 months before the
onset of SSTI were excluded.
Swab cultures, S. aureus species conﬁrmation, antimicrobial
susceptibility testing and testing for the mecA and Panton–
Valentin leukocidin (PVL) (lukS/lukF) genes by PCR were per-
formed as described elsewhere [8]. Trimethoprim-resistant
strains were tested for the presence of dfrA, dfrK and dfrG by
PCR [6]. The intrinsic dfrB genes of trimethoprim-resistant
strains without known dfr resistance genes were sequenced
and analysed for possible chromosomal mutations [6]. The
tetracycline resistance genes (tet(L), tet(K), tet(M) and tet(O))
were detected by PCR [9].
The study was approved by the Ethics Committee, Faculty of
Medicine, Eberhard Karls Universität Tübingen and by the
institutional review boards of the contributing centres, if
necessary.
Of 318 submissions from independent SSTI cases [8], 62%
(196/318) were caused by S. aureus. Thirty-eight per cent (75/
196) of imported S. aureus were trimethoprim-resistant and
21% (41/196) were also resistant to a combination of
trimethoprim–sulfamethoxazole. Twelve per cent (23/196) of
all S. aureus isolates were MRSA. Of these, 17% (4/23) exhibited
concomitant trimethoprim–sulfamethoxazole resistance and
30% (7/23) trimethoprim resistance, respectively.
Among 66 S. aureus strains collected from German patients
with acute SSTI, there was one trimethoprim–sulfamethoxa-
zole-resistant strain, but the remaining isolates were susceptible
to trimethoprim and trimethoprim–sulfamethoxazole. Five per
cent (3/66) of isolates in the control group were PVL+, and
none was MRSA.
Imported S. aureus was more often resistant to trimethoprim
and trimethoprim–sulfamethoxazole than isolates from
autochthonous infections with the highest odds ratio estimates
for imports from South Asia, followed by Africa, Latin America
and South-East Asia (Table 1). Besides, trimethoprim and
trimethoprim–sulfamethoxazole resistance was positively
associated with abscess formation, presence of PVL-encoding
genes, and particular spa types (Table 1).
Altogether dfrG accounted for 92% (69/75) of all trimetho-
prim resistance, whereas 7% (5/75) was due to dfrA, and only
one strain carried the F98Y dfrB mutation. We did not ﬁnd any
dfrK-mediated trimethoprim resistance. Although dfrG was the
predominant trimethoprim-resistance mechanism in isolates
from Africa (38/40), South Asia (21/22) and South-East Asia (7/
8) (Table 1), isolates from South America were found to also
carry a substantial proportion of dfrA (2/5) next to dfrG (3/5)
genes. Looking at all imported isolates, the presence of dfrG was
not restricted to particular spa types, but, when compared withClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectall other spa types, it was statistically more often present in
t355, t021, t084 and t314 (Table 1).
DfrG-mediated trimethoprim resistance was associated with
resistance to tetracycline and ciproﬂoxacin, but not with
resistance to methicillin (Table 1). Of 23 isolates resistant to
both tetracycline and trimethoprim with identiﬁable
tetracycline-resistance genes, 20 carried a combination of dfrG
and tet(K), two of dfrG and tet(M), and one isolate an F98Y
mutated dfrB and tet(K). The common combination of dfrG and
tet(K) (n = 20) clustered in spa t355 (n = 7) and t314 (n = 4),
explaining all trimethoprim/tetracycline co-resistance observed
within these genotypes.
One of 66 S. aureus in the control group was trimetho-
prim–sulfamethoxazole and penicillin-resistant, dfrG-positive,
spa type t314; and isolated from an abscess (PVL+). Follow up
with the treating physician did not reveal exposure abroad 3
months before onset of the SSTI.
Analysing isolates imported from six major regions of the
world to Europe, we show that dfrG accounts for 92% of all
trimethoprim resistance in S. aureus from human SSTI. Based on
its global abundance, and by drawing on our previous and
similar ﬁndings in S. aureus in Africa and in a limited number of
isolates imported from there [6], we propose that dfrG is
globally the most common genetic determinant of trimetho-
prim resistance in S. aureus causing human infection.
In the present study, the majority of trimethoprim-resistant
S. aureus from South and South-East Asia harboured dfrG. This
is in sharp contrast to one report of that region describing dfrG
in MRSA causing a clonal outbreak in a hospital in Chiang Mai,
Thailand [10]. Similarly, we found dfrG to be the predominant
genetic determinant of trimethoprim resistance in isolates from
Latin America. To the best of our knowledge, this is the ﬁrst
report of dfrG in S. aureus from human infection from that
region. Therefore, and in conjunction with our published
ﬁndings from Africa [6], we present ample evidence that dfrA
and the F98Y mutation of the autochthonous dfrB gene, i.e.
those genetic elements that are commonly referred to as the
key genetic determinants of trimethoprim resistance [11,12]
are, on a global scale, less commonly found than dfrG in
trimethoprim-resistant S. aureus causing human infection.
In line with recent work that successfully demonstrated the
location of dfrG on a mobile genetic element in S. aureus causing
human infections [13], its presence in imports was not clonally
restricted, further supporting its mobile nature. Interestingly,
research in Staphylococcus pseudintermedius colonizing cats and
dogs demonstrated that 90% of trimethoprim resistance in that
species is dfrG-mediated [14], inviting a further hypothesis on a
cross-species transfer, from animal to human staphylococci.
In our control group one S. aureus (spa type t314) was PVL+
trimethoprim–sulfamethoxazole resistant. On further scrutiny,ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1095.e5–1095.e9
TABLE 1. Trimethoprim–sulfamethoxazole-resistance and trimethoprim-resistance in 196 Staphylococcus aureus isolates from imported skin and soft-tissue infections
Characteristic
Trimethoprim–sulfamethoxazole (TMP-SMZ) Trimethoprim (TMP) dfr genes
Resistant Susceptible
OR (95% CI) p
Resistant Susceptible
OR (95% CI) p
dfrG dfrA dfrB F98Y
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Total 196 41 (21) 155 (79) 75 (38) 121 (62) 69/75 (92) 5/75 (7) 1/75 (1)
Destination
Africa 64 19 (30) 45 (70) 27.4 (4.0–1157.2) <0.0001 40 (63) 24 (37) 108.3 (15.9–4448.5) <0.0001 38/40 (95) 2/40 (5) 0
Latin America 32 4 (13) 28 (87) 14.6 (3.2–132.7) 0.02 5 (16) 27 (84) 12.0 (1.2–577.7) 0.006 3/5 (60) 2/5 (40) 0
South Asia 32 14 (44) 18 (56) 50.6 (6.6–2168.6) <0.0001 22 (69) 10 (21) 143.0 (17.8–5984.5) <0.0001 21/22 (95) 1/22 (5) 0
South-East Asia 57 4 (7) 53 (93) 4.9 (0.5–245.2) 0.1 8 (14) 49 (86) 10.6 (1.3–477.9) 0.008 7/8 (87) 0 1 (13)
Central Asia 3 0 3 N 0.4 0 3 N 0.2 0 0 0
Oceania 8 0 8 N 0.1 0 8 N 0.02 0 0 0
Germany (controls) 66 1 (2) 65 (98) 1.0 n/a 1 (2) 65 (97) 1.0 n/a 1/1 (100) 0 0
Type of lesiona
Ulcer 53 8 (15) 45 (85) 0.6 (0.3–1.4) 0.2 13 (25) 40 (75) 0.4 (0.2–0.9) 0.02 12/13 (92) 0/13 1/13 (8)
Abscess 132 32 (24) 100 (76) 2.0 (0.9–4.4) 0.1 58 (44) 74 (56) 2.2 (1.1–4.2) 0.02 53/58 (91) 5/58 (9) 0
Other 10 1 (10) 9 (90) 0.4 (0.05–3.3) 0.4 4 (40) 6 (60) 1.1 (0.3–4.0) 0.9 4/4 (100) 0 0
Pathogenb
PVL-negative 74 7 (9) 67 (91) 1.0 n/a 14 (19) 60 (81) 1.0 n/a 12/14 (86) 1/14 (7) 1/14 (7)
PVL-positive 122 34 (28) 88 (72) 3.7 (1.5–8.9) 0.003 61 (50) 61 (50) 4.3 (2.2–8.5) <0.001 57/61 (93) 4/61 (7) 0
t002 8 0 8 (100) n/a 0.1 0 8 (100) n/a 0.02 – – –
t008 12 1 (8) 11 (92) 0.3 (0.04–2.6) 0.3 1 (8) 11 (92) 0.13 (0.02–1.1) 0.06 1/1 (100) – –
t021 11 8 (73) 3 (27) 12.3 (3.1–48.8) <0.001 10 (91) 1 (9) 18.0 (2.3–147.4) 0.006 10/10 (100) – –
t084 9 4 (44) 5 (56) 3.2 (0.8–12.7) 0.09 8 (89) 1 (11) 14.3 (1.75–117.0) 0.02 8/8 (100) – –
t355 10 5 (50) 5 (50) 4.2 (1.1–15.1) 0.03 10 (100) 0 (0) n/a <0.001 10/10 (100) – –
t314 7 5 (71) 2 (29) 10.6 (2.0–57.0) 0.006 6 (86) 1 (14) 10.4 (1.2–88.5) 0.03 6/6 (100) – –
t189 5 0 5 (100) n/a 0.2 0 (0) 5 (100) n/a 0.08 – – –
t159 5 1 (20) 4 (80) 0.9 (0.1–8.7) 1 3 (60) 2 (40) 2.5 (0.4–15–2) 0.3 3/3 (100) – –
t127 8 1 (13) 7 (87) 0.5 (0.06–4.4) 0.6 2 (25) 6 (75) 0.5 (0.1–2.7) 0.4 2/2 (100) – –
Co-resistancec
Methicillin/mecAd 23 4 (17) 19 (83) 0.8 (0.2–2.4) 0.7 7 (30) 16 (70) 0.7 (0.3–1.7) 0.4 4/7 (57)e 3/7 (43)f 0
Any other non-β-lactamg 85 30 (35) 55 (65) 5.0 (2.3–10.7) <0.001 47 (55) 38 (45) 3.7 (2.0–6.7) <0.001 45/47 (96) 1/47 (2) 1/47 (2)
Tetracyclineh 40 15 (38) 25 (62) 3.0 (1.4–6.5) 0.005 24 (60) 16 (40) 3.1 (1.5–6.3) 0.002 23/24 (96) 0 1/24 (4)
Tet(K) 32 15 (47) 17 (53) 4.7 (2.0–10.5) <0.001 21 (66) 11 (34) 3.9 (1.7–8.6) 0.001 20/21 (95) 0 1/21 (5)
Tet(M) 3 0 3 (100) n/a 0.4 2 (67) 1 (33) 3.3 (0.3–36.9) 0.3 2/2 (100) 0 0
Ciproﬂoxacin 26 16 (62) 10 (38) 9.3 (3.8–22.8) <0.001 22 (85) 4 (15) 12.1 (4.0–37.0) <0.001 21/22 (95) 1/22 (5) 0
Data are number (row %) of trimethoprim–sulfamethoxazole (TMP-SMZ) and trimethoprim (TMP) resistant isolates (left and central column) and number (row %) of TMP-resistant isolates carrying a respective dfr gene (right column). Odds ratios
(OR), p-values, 95% conﬁdence intervals (95% CI) from univariable logistic regression.
Abbreviations: PVL, Panton–Valentine leukocidin; mecA, gene conferring methicillin resistance in S. aureus; dfrG/dfrA, accessory genes conferring high level trimethoprim resistance in S. aureus; dfrB, mutation F98Y of the autochthonous
dehydrofolate-encoding gene conferring low-level trimethoprim resistance.
aData for type of lesion missing for one patient; ORs comparing the odds of TMP-SMZ or TMP resistance in S. aureus of a given type of lesion (i.e. ulcer, abscess, other type) with the odds of TMP-SMZ or TMP resistance among the other types of
lesions combined.
bOnly spa types with ﬁve or more isolates are displayed; ORs comparing the odds of TMP-SMZ or TMP resistance in S. aureus of a given spa type with the odds of TMP-SMZ or TMP resistance among all remaining spa types combined.
cCo-resistance tested for cefoxitin, clindamycin, erythromycin, ciproﬂoxacin, tetracycline, gentamicin and rifampicin; only statistically signiﬁcant associations are displayed; ORs comparing the odds of TMP-SMZ or TMP resistance in S. aureus with a
given co-resistance (i.e. methicillin, non-β-lactam other than TMP-SMZ, tetracycline, ciproﬂoxacin) to the odds of TMP-SMZ or TMP resistance among S. aureus without that type of co-resistance.
dMRSA was deﬁned as resistance to cefoxitin by agar diffusion and conﬁrmed by PCR for mecA.
espa types (country of origin) of dfrG carrying MRSA where t008 (Suriname), none typeable (The Philippines), t657 (India), t304 (India).
fspa types (country of origin) of dfrA carrying MRSA where t148 (Costa Rica), t186 (Madagascar), t10437 (Costa Rica).
gDeﬁned as co-resistance to any of clindamycin, erythromycin, ciproﬂoxacin, tetracycline, gentamicin and rifampicin.
hNo strains with tet(L) or tet(O) detected; n = 5 strains with unidentiﬁed genetic determinant of tetracycline resistance.
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gions in the last 3 months. Staphylococcus aureus spa t314 is one
of the most common spa types found in African isolates [6,15]
fostering speculations about trimethoprim–sulfamethoxazole-
resistant clones being introduced and established in autoch-
thonous populations.
We found co-resistances between anti-folate compounds
and tetracycline. Tetracycline resistance is mediated by either
tet(K) and tet(L) located on a plasmid or by tet(M) and tet(O)
located on a transposon or integrated in the chromosome [16].
In any of these cases, transmission may be linked to other
resistance genes, such as the dfr genes. Indeed, Kadlec and
Schwarz have identiﬁed a plasmid-borne resistance gene cluster
carrying dfr(K) and tet(L) in S. aureus ST398 from swine [17].
Furthermore, genome sequencing of a virulent MRSA strain
ST239 revealed the co-localization of tet(M) and dfrG on a
transposon Tn5801 [18]. Our observations on the strong as-
sociation of dfrG with tet(K) in S. aureus causing human infection
suggest that there may be a similar genetic link between these
two resistance genes. This would pose a major threat to global
public health, as both tetracycline and trimethoprim–sulfa-
methoxazole are the two compounds of choice for the treat-
ment of moderately severe SSTI caused by MRSA according to
IDSA guidelines [3].
We observed a strong and statistically signiﬁcant association
between the presence of the genes encoding for PVL and
trimethoprim–sulfamethoxazole resistance (Table 1). In
extension to a recent report by Kraef et al. [19], we could
reproduce this ﬁnding in immunocompetent patients and a
clonally more diverse S. aureus population. Considering that
dfrG in S. aureus is likely to be localized on a genetic element
that may have potential to accept other resistance genes such as
tet(K), its strong association with PVL is of concern because,
under intermittent antibiotic pressure, the combined presence
of virulence and resistance genes will be particularly efﬁcient in
propagating the hosting S. aureus clone.
In summary, we provide ample evidence that dfrG is globally
the predominant genetic determinant of trimethoprim resis-
tance in S. aureus causing human infection. Frequent import,
location on a mobile genetic element, and a potential associa-
tion with tet(K) are features of an emerging resistance gene that
has the potential to rapidly limit our antimicrobial treatment
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